Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDH-Combi in metastatic solid tumors
NCT06296056Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SDH-Combi in Adenocarcinoma, sponsored by Seoul National University Hospital. Primary endpoints: Treatment-related adverse events at 6 months and Serious adverse events at 6 months. Started Aug 2024; status: completed.
02
Drugs
SDH-Combi
03
Conditions
Adenocarcinoma
Beyond the preview
Go deeper on NCT06296056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06296056.